{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:31:07Z","timestamp":1786980667938,"version":"build-2736575974"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Jpn J Ophthalmol"],"published-print":{"date-parts":[[2021,3]]},"DOI":"10.1007\/s10384-020-00793-6","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T02:47:23Z","timestamp":1610160443000},"page":"191-198","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Validation of systemic parameters for the diagnosis of ocular sarcoidosis"],"prefix":"10.1007","volume":"65","author":[{"given":"Kayo","family":"Suzuki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichi","family":"Namba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuomi","family":"Mizuuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiju","family":"Iwata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takako","family":"Ito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keitaro","family":"Hase","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyoshi","family":"Kitaichi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susumu","family":"Ishida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"key":"793_CR1","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S0140-6736(03)12888-7","volume":"361","author":"RP Baughman","year":"2003","unstructured":"Baughman RP, Lower EE, du Bois RM. Sarcoidosis. Lancet. 2003;361:1111\u20138.","journal-title":"Lancet"},{"key":"793_CR2","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1136\/bjo.45.7.461","volume":"45","author":"RP Crick","year":"1961","unstructured":"Crick RP, Hoyle C, Smellie H. The eyes in sarcoidosis. Br J Ophthalmol. 1961;45:461\u201381.","journal-title":"Br J Ophthalmol"},{"key":"793_CR3","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/0002-9394(86)90001-2","volume":"102","author":"DA Jabs","year":"1986","unstructured":"Jabs DA, Johns CJ. Ocular involvement in chronic sarcoidosis. Am J Ophthalmol. 1986;102:297\u2013301.","journal-title":"Am J Ophthalmol"},{"key":"793_CR4","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0896-1549(02)00021-4","volume":"15","author":"NP Jones","year":"2002","unstructured":"Jones NP. Sarcoidosis and uveitis. Ophthalmol Clin North Am. 2002;15:319\u201326.","journal-title":"Ophthalmol Clin North Am"},{"key":"793_CR5","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/s10384-006-0413-2","volume":"51","author":"T Kawaguchi","year":"2007","unstructured":"Kawaguchi T, Hanada A, Horie S, Sugamoto Y, Sugita S, Mochizuki M. Evaluation of characteristic ocular signs and systemic investigations in ocular sarcoidosis patients. Jpn J Ophthalmol. 2007;51:121\u20136.","journal-title":"Jpn J Ophthalmol"},{"key":"793_CR6","first-page":"452","volume":"36","author":"K Ohara","year":"1992","unstructured":"Ohara K, Okubo A, Sasaki H, Kamata K. Intraocular manifestations of systemic sarcoidosis. Jpn J Ophthalmol. 1992;36:452\u20137.","journal-title":"Jpn J Ophthalmol"},{"key":"793_CR7","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1007\/s10384-012-0158-z","volume":"56","author":"N Ohguro","year":"2012","unstructured":"Ohguro N, Sonoda KH, Takeuchi M, Matsumura M, Mochizuki M. The 2009 prospective multi-center epidemiologic survey of uveitis in Japan. Jpn J Ophthalmol. 2012;56:432\u20135.","journal-title":"Jpn J Ophthalmol"},{"key":"793_CR8","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1136\/bjo.65.5.348","volume":"65","author":"DJ Spalton","year":"1981","unstructured":"Spalton DJ, Sanders MD. Fundus changes in histologically confirmed sarcoidosis. Br J Ophthalmol. 1981;65:348\u201358.","journal-title":"Br J Ophthalmol"},{"key":"793_CR9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1097\/00006982-200001000-00002","volume":"20","author":"JE Thorne","year":"2000","unstructured":"Thorne JE, Brucker AJ. Choroidal white lesions as an early manifestation of sarcoidosis. Retina. 2000;20:8\u201315.","journal-title":"Retina"},{"key":"793_CR10","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.ophtha.2017.07.006","volume":"125","author":"NR Acharya","year":"2018","unstructured":"Acharya NR, Browne EN, Rao N, Mochizuki M, IOSW Group. Distinguishing features of ocular sarcoidosis in an international cohort of uveitis patients. Ophthalmology. 2018;125:119\u201326.","journal-title":"Ophthalmology"},{"key":"793_CR11","doi-asserted-by":"publisher","first-page":"e0147258","DOI":"10.1371\/journal.pone.0147258","volume":"11","author":"E Gundlach","year":"2016","unstructured":"Gundlach E, Hoffmann MM, Prasse A, Heinzelmann S, Ness T. Interleukin-2 receptor and angiotensin-converting enzyme as markers for ocular sarcoidosis. PLoS One. 2016;11:e0147258.","journal-title":"PLoS One"},{"key":"793_CR12","doi-asserted-by":"publisher","first-page":"1352","DOI":"10.1001\/jamaophthalmol.2017.4771","volume":"135","author":"F Groen-Hakan","year":"2017","unstructured":"Groen-Hakan F, Eurelings L, ten Berge JC, Laar J, Ramakers CRB, Dik WA, et al. Diagnostic value of serum-soluble interleukin 2 receptor levels vs angiotensin-converting enzyme in patients with sarcoidosis-associated uveitis. JAMA Ophthalmol. 2017;135:1352\u20138.","journal-title":"JAMA Ophthalmol"},{"key":"793_CR13","doi-asserted-by":"publisher","first-page":"1372","DOI":"10.1136\/bjophthalmol-2014-306353","volume":"99","author":"C Febvay","year":"2015","unstructured":"Febvay C, Kodjikian L, Maucort-Boulch D, Perard L, Iwaz J, Jamilloux Y, et al. Clinical features and diagnostic evaluation of 83 biopsy-proven sarcoid uveitis cases. Br J Ophthalmol. 2015;99:1372\u20136.","journal-title":"Br J Ophthalmol"},{"key":"793_CR14","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1177\/000456328902600102","volume":"26","author":"PR Studdy","year":"1989","unstructured":"Studdy PR, Bird R. Serum angiotensin converting enzyme in sarcoidosis\u2013its value in present clinical practice. Ann Clin Biochem. 1989;26:13\u20138.","journal-title":"Ann Clin Biochem"},{"key":"793_CR15","doi-asserted-by":"publisher","first-page":"2007","DOI":"10.1016\/S0161-6420(95)30763-4","volume":"102","author":"WJ Power","year":"1995","unstructured":"Power WJ, Neves RA, Rodriguez A, Pedroza-Seres M, Foster CS. The value of combined serum angiotensin-converting enzyme and gallium scan in diagnosing ocular sarcoidosis. Ophthalmology. 1995;102:2007\u201311.","journal-title":"Ophthalmology"},{"key":"793_CR16","doi-asserted-by":"publisher","first-page":"1418","DOI":"10.1136\/bjophthalmol-2018-313356","volume":"103","author":"M Mochizuki","year":"2019","unstructured":"Mochizuki M, Smith JR, Takase H, Kaburaki T, Acharya NR, Rao NA, et al. Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis. Br J Ophthalmol. 2019;103:1418\u201322.","journal-title":"Br J Ophthalmol"},{"key":"793_CR17","unstructured":"The Japanese society of sarcoidosis and other granulomatous disorders (JSSOG). Diagnostic standard and guideline for sarcoidosis-2015. http:\/\/jssog.com\/www\/top\/shindan\/shindan2-1new.html. Accessed 30 March 2020 (in Japanese)."},{"key":"793_CR18","first-page":"89","volume":"27","author":"The Japanese society of sarcoidosis and other granulomatous disorders (JSSOG)","year":"2007","unstructured":"The Japanese society of sarcoidosis and other granulomatous disorders (JSSOG). Diagnostic standard and guideline for sarcoidosis-2006. Jpn J Sarcoidosis\/Other Granulomatous Disord. 2007;27:89\u2013102 (in Japanese).","journal-title":"Jpn J Sarcoidosis\/Other Granulomatous Disord"},{"key":"793_CR19","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/1346-8138.13792","volume":"44","author":"C Thi Hong Nguyen","year":"2017","unstructured":"Thi Hong Nguyen C, Kambe N, Kishimoto I, Ueda-Hayakawa I, Okamoto H. Serum soluble interleukin-2 receptor level is more sensitive than angiotensin-converting enzyme or lysozyme for diagnosis of sarcoidosis and may be a marker of multiple organ involvement. J Dermatol. 2017;44:789\u201397.","journal-title":"J Dermatol"},{"key":"793_CR20","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1183\/09031936.03.00010403","volume":"21","author":"MW Ziegenhagen","year":"2003","unstructured":"Ziegenhagen MW, Rothe ME, Schlaak M, M\u00fclller-Quernheim J. Bronchoalveolar and serological parameters reflecting the severity of sarcoidosis. Eur Respir J. 2003;21:407\u201313.","journal-title":"Eur Respir J"},{"key":"793_CR21","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.intimp.2015.01.015","volume":"25","author":"S Gungor","year":"2015","unstructured":"Gungor S, Ozseker F, Yalcinsoy M, Akkaya E, Can G, Eroglu H, et al. Conventional markers in determination of activity of sarcoidosis. Int Immunopharmacol. 2015;25:174\u20139.","journal-title":"Int Immunopharmacol"},{"key":"793_CR22","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1378\/chest.124.1.186","volume":"124","author":"JC Grutters","year":"2003","unstructured":"Grutters JC, Fellrath JM, Mulder L, Janssen R, van den Bosch JM, van Velzen-Blad H. Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation. Chest. 2003;124:186\u201395.","journal-title":"Chest"},{"key":"793_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1016\/j.rmed.2014.11.009","volume":"109","author":"AD Vorselaars","year":"2015","unstructured":"Vorselaars AD, van Moorsel CH, Zanen P, Ruven HJ, Claessen AM, van Velzen-Blad H, et al. ACE and sIL-2R correlate with lung function improvement in sarcoidosis during methotrexate therapy. Respir Med. 2015;109:279\u201385.","journal-title":"Respir Med"},{"key":"793_CR24","doi-asserted-by":"publisher","first-page":"1128","DOI":"10.1378\/chest.102.4.1128","volume":"102","author":"Y Ina","year":"1992","unstructured":"Ina Y, Takada K, Sato T, Yamamoto M, Noda M, Morishita M. Soluble interleukin 2 receptors in patients with sarcoidosis. Possible origin. Chest. 1992;102:1128\u201333.","journal-title":"Chest"},{"key":"793_CR25","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1378\/chest.98.5.1125","volume":"98","author":"N Keicho","year":"1990","unstructured":"Keicho N, Kitamura K, Takaku F, Yotsumoto H. Serum concentration of soluble interleukin-2 receptor as a sensitive parameter of disease activity in sarcoidosis. Chest. 1990;98:1125\u20139.","journal-title":"Chest"},{"key":"793_CR26","doi-asserted-by":"publisher","first-page":"759","DOI":"10.1164\/ajrccm\/137.4.759","volume":"137","author":"EC Lawrence","year":"1988","unstructured":"Lawrence EC, Brousseau KP, Berger MB, Kurman CC, Marcon L, Nelson DL. Elevated concentrations of soluble interleukin-2 receptors in serum samples and bronchoalveolar lavage fluids in active sarcoidosis. Am Rev Respir Dis. 1988;137:759\u201364.","journal-title":"Am Rev Respir Dis"},{"key":"793_CR27","doi-asserted-by":"publisher","first-page":"113","DOI":"10.2169\/internalmedicine1962.30.113","volume":"30","author":"F Ogushi","year":"1991","unstructured":"Ogushi F, Sone S, Singh SM, Tani T, Ozaki S, Yasuoka T. Elevated level of soluble interleukin-2 receptor in bronchoalveolar lavage fluid from sarcoidosis patients. Jpn J Med. 1991;30:113\u20137.","journal-title":"Jpn J Med"},{"key":"793_CR28","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1007\/s00417-003-0762-1","volume":"241","author":"N Kitaichi","year":"2003","unstructured":"Kitaichi N, Kotake S, Shibuya H, Yamada Y, Chiba H, Namba K, et al. Increase of KL-6 in sera of uveitis patients with sarcoidosis. Graefe\u2019s Arch Clin Exp Ophthalmol. 2003;241:879\u201383.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"793_CR29","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/nri3156","volume":"12","author":"O Boyman","year":"2012","unstructured":"Boyman O, Sprent J. The role of interleukin-2 during homeostasis and activation of the immune system. Nat Rev Immunol. 2012;12:180\u201390.","journal-title":"Nat Rev Immunol"},{"key":"793_CR30","doi-asserted-by":"publisher","first-page":"185","DOI":"10.3109\/10408368609110273","volume":"24","author":"OB Selroos","year":"1986","unstructured":"Selroos OB. Biochemical markers in sarcoidosis. Crit Rev Clin Lab Sci. 1986;24:185\u2013216.","journal-title":"Crit Rev Clin Lab Sci"},{"key":"793_CR31","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1378\/chest.09-1975","volume":"137","author":"S Miyoshi","year":"2010","unstructured":"Miyoshi S, Hamada H, Kadowaki T, Hamaguchi N, Ito R, Irifune K, et al. Comparative evaluation of serum markers in pulmonary sarcoidosis. Chest. 2010;137:1391\u20137.","journal-title":"Chest"},{"key":"793_CR32","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.jjcc.2019.05.007","volume":"74","author":"Y Baba","year":"2019","unstructured":"Baba Y, Kubo T, Yamanaka S, Ochi Y, Hirota T, Yamazaki N, et al. Reconsideration of the cut-off value of angiotensin-converting enzyme for screening of sarcoidosis in Japanese patients. J Cardiol. 2019;74:507\u201311.","journal-title":"J Cardiol"},{"issue":"3\u20134","key":"793_CR33","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1007\/BF00153496","volume":"72","author":"A Rothova","year":"1989","unstructured":"Rothova A, Alberts C, Glasius E, Kijlstra A, Buitenhuis HJ, Breebaart AC. Risk factors for ocular sarcoidosis. Doc Ophthalmol. 1989;72(3\u20134):287\u201396.","journal-title":"Doc Ophthalmol"},{"key":"793_CR34","first-page":"237","volume":"32","author":"R Agrawal","year":"2015","unstructured":"Agrawal R, Gonzalez-Lopez JJ, Meier F, Gupta B, Pavesio CE. Ocular and systemic features of sarcoidosis and correlation with the International Workshop for Ocular Sarcoidosis diagnostic criteria. Sarcoidosis Vasc Diffuse Lung Dis. 2015;32:237\u201345.","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"793_CR35","doi-asserted-by":"publisher","first-page":"458","DOI":"10.1097\/MCP.0000000000000409","volume":"23","author":"SJ Yang","year":"2017","unstructured":"Yang SJ, Salek S, Rosenbaum JT. Ocular sarcoidosis: new diagnostic modalities and treatment. Curr Opin Pulm Med. 2017;23:458\u201367.","journal-title":"Curr Opin Pulm Med"},{"key":"793_CR36","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1007\/s12149-007-0060-9","volume":"21","author":"T Kita","year":"2007","unstructured":"Kita T, Watanabe S, Yano F, Hayashi K, Yamamoto M, Iwasaki Y, et al. Clinical significance of the serum IL-2R level and Ga-67 scan findings in making a differential diagnosis between sarcoidosis and non-Hodgkin\u2019s lymphoma. Ann Nucl Med. 2007;21:499\u2013503.","journal-title":"Ann Nucl Med"},{"key":"793_CR37","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/j.1600-0609.1995.tb01619.x","volume":"54","author":"R Stasi","year":"1995","unstructured":"Stasi R, Zinzani L, Galieni P, Lauta VM, Damasio E, Dispensa E, et al. Clinical implications of cytokine and soluble receptor measurements in patients with newly-diagnosed aggressive non-Hodgkin\u2019s lymphoma. Eur J Haematol. 1995;54:9\u201317.","journal-title":"Eur J Haematol"},{"key":"793_CR38","first-page":"474","volume":"11","author":"J Murakami","year":"2019","unstructured":"Murakami J, Arita K, Wada A, Mihara H, Origasa H, Kigawa M, et al. Serum soluble interleaukin-2 receptor levels for screening for malignant lymphomas and differential diagnosis from other conditions. Mol Clin Oncol. 2019;11:474\u201382.","journal-title":"Mol Clin Oncol"},{"key":"793_CR39","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1016\/j.survophthal.2017.08.005","volume":"63","author":"TJ Rubinstein","year":"2018","unstructured":"Rubinstein TJ, Aziz HA, Bellerive C, Sires BS, Hing AW, Habermehl G, et al. Ocular\/adnexal lymphoma: dissimilar to systemic lymphoma. Surv Ophthalmol. 2018;63:381\u20138.","journal-title":"Surv Ophthalmol"},{"key":"793_CR40","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.survophthal.2013.12.001","volume":"59","author":"MS Sagoo","year":"2014","unstructured":"Sagoo MS, Mehta H, Swampillai AJ, Cohen VM, Amin SZ, Plowman PN, et al. Primary intraocular lymphoma. Surv Opthalmol. 2014;59:503\u201316.","journal-title":"Surv Opthalmol"}],"container-title":["Japanese Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-020-00793-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10384-020-00793-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10384-020-00793-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,18]],"date-time":"2021-03-18T16:39:36Z","timestamp":1616085576000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10384-020-00793-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2021,3]]}},"alternative-id":["793"],"URL":"https:\/\/doi.org\/10.1007\/s10384-020-00793-6","relation":{},"ISSN":["0021-5155","1613-2246"],"issn-type":[{"value":"0021-5155","type":"print"},{"value":"1613-2246","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]},"assertion":[{"value":"14 April 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"K. Suzuki, None; K. Namba, Grant, Speaker fee (Mitsubishi Tanabe, AbbVie, Eisai), Grant (EP-CRSU), Speaker fee (HOYA, Alcon, Pfizer, AstraZeneca, Novartis, Kowa, Chugai, Senju, Santen); K. Mizuuchi, None; D. Iwata, Speaker fee (Alcon, Santen, AbbVie, Mitsubishi Tanabe, Kowa); T. Ito, None; K. Hase, None; N. Kitaichi, Speaker fee (Santen, AbbVie, Celgene, AMO), Grant (Alcon, Novartis); S. Ishida, None.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}